Insider Buying: Aptose Biosciences Inc. (NASDAQ:APTO) CEO Purchases 100,000 Shares of Stock

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice acquired 100,000 shares of the stock in a transaction on Monday, November 25th. The stock was bought at an average price of $0.20 per share, with a total value of $20,000.00. Following the transaction, the chief executive officer now directly owns 613,252 shares in the company, valued at approximately $122,650.40. This represents a 19.48 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Aptose Biosciences Price Performance

Shares of NASDAQ:APTO opened at $0.18 on Friday. Aptose Biosciences Inc. has a 1-year low of $0.13 and a 1-year high of $2.91. The business has a 50-day moving average price of $0.36 and a two-hundred day moving average price of $0.58.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on APTO shares. HC Wainwright decreased their price target on shares of Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. StockNews.com assumed coverage on Aptose Biosciences in a report on Friday. They set a “hold” rating on the stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.